Is chewing khat associated with mental health disorders? A scoping review of the content and quality of the current evidence base.
Catha edulis
Khat
Mental health disorders
Psychological distress
Scoping review
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
27 06 2023
27 06 2023
Historique:
received:
24
02
2023
accepted:
05
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
Khat (Catha edulis) is a plant commonly found in the horn of Africa whose leaves are chewed for their psycho-stimulant effects. Several studies have demonstrated the association between khat use and mental health problems. Nevertheless, evidence is mixed and inconsistent, warranting further review of available studies. This scoping review is aimed at investigating the content and quality of evidence base on the associations between khat use and mental health disorders and suggesting avenues for further research. We used a scoping review methodology to map the existing evidence using PubMed, SCOPUS, Embase, and CINAHL databases. Primary studies focusing on the association between any pattern of khat use and any form of mental health disorders are included. The review focused on all age groups, any study design, all geographical locations, and any publication year. The terms used for searching eligible studies include khat, mental disorders, and various alternative terminologies. Narrative review is employed to present findings. 7,121 articles were found, of which 108 were eligible, conducted across 12 different countries. The majority of the studies was done during the last ten years and the studies mostly employed cross-sectional design. About 10 different categories of mental health disorders have been identified as showing associations with khat use. Despite many contradictory findings between the studies, most of the evidence base suggests that khat use is associated with mental health disorders. Non-specific psychological distress is the most frequently mentioned mental health problem (reported in 26.9% of the studies). Khat use as a predictor variable is mostly assessed using a 'yes/no' category, and as a result, dose-dependent effects of khat use on mental health are not given much consideration. Although most of the studies associate khat use with mental health disorders, the causal relationships are inconclusive given the cross-sectional design of the studies, and the presence of potential confounders and several forms of biases. Available studies also report contradictory findings. Further studies are recommended using prospective designs, standardized and valid measures of khat use, and focusing on specific types of mental health disorders.
Sections du résumé
BACKGROUND
Khat (Catha edulis) is a plant commonly found in the horn of Africa whose leaves are chewed for their psycho-stimulant effects. Several studies have demonstrated the association between khat use and mental health problems. Nevertheless, evidence is mixed and inconsistent, warranting further review of available studies. This scoping review is aimed at investigating the content and quality of evidence base on the associations between khat use and mental health disorders and suggesting avenues for further research.
METHODS
We used a scoping review methodology to map the existing evidence using PubMed, SCOPUS, Embase, and CINAHL databases. Primary studies focusing on the association between any pattern of khat use and any form of mental health disorders are included. The review focused on all age groups, any study design, all geographical locations, and any publication year. The terms used for searching eligible studies include khat, mental disorders, and various alternative terminologies. Narrative review is employed to present findings.
RESULTS
7,121 articles were found, of which 108 were eligible, conducted across 12 different countries. The majority of the studies was done during the last ten years and the studies mostly employed cross-sectional design. About 10 different categories of mental health disorders have been identified as showing associations with khat use. Despite many contradictory findings between the studies, most of the evidence base suggests that khat use is associated with mental health disorders. Non-specific psychological distress is the most frequently mentioned mental health problem (reported in 26.9% of the studies). Khat use as a predictor variable is mostly assessed using a 'yes/no' category, and as a result, dose-dependent effects of khat use on mental health are not given much consideration.
CONCLUSION
Although most of the studies associate khat use with mental health disorders, the causal relationships are inconclusive given the cross-sectional design of the studies, and the presence of potential confounders and several forms of biases. Available studies also report contradictory findings. Further studies are recommended using prospective designs, standardized and valid measures of khat use, and focusing on specific types of mental health disorders.
Identifiants
pubmed: 37370160
doi: 10.1186/s13011-023-00545-y
pii: 10.1186/s13011-023-00545-y
pmc: PMC10303364
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Informations de copyright
© 2023. The Author(s).
Références
BMC Psychiatry. 2019 May 7;19(1):137
pubmed: 31064338
Addiction. 2004 Jan;99(1):61-5
pubmed: 14678063
Neuropsychiatr Dis Treat. 2017 Nov 08;13:2803-2812
pubmed: 29184411
Pan Afr Med J. 2013 Jul 11;15:95
pubmed: 24198889
East Mediterr Health J. 2017 May 01;23(3):161-167
pubmed: 28493262
Ann Gen Psychiatry. 2020 Mar 09;19:16
pubmed: 32165908
Wien Klin Wochenschr. 2009;121(19-20):604-14
pubmed: 19921126
Addict Behav. 2017 Oct;73:178-184
pubmed: 28531823
Drug Alcohol Depend. 1986 Sep;18(1):97-105
pubmed: 2877839
Psychol Res Behav Manag. 2021 Mar 01;14:261-273
pubmed: 33688279
Addiction. 2013 Oct;108(10):1855-62
pubmed: 23714286
Transcult Psychiatry. 2011 Sep;48(4):455-72
pubmed: 21911510
BMC Psychiatry. 2021 Mar 4;21(1):127
pubmed: 33663452
East Afr Med J. 1981 Feb;58(2):130-5
pubmed: 6113948
PLoS One. 2018 Mar 6;13(3):e0189312
pubmed: 29509771
Addict Biol. 2005 Dec;10(4):299-307
pubmed: 16318950
PLoS One. 2013 Jun 11;8(6):e65504
pubmed: 23776490
East Afr Med J. 2004 Sep;81(9):468-73
pubmed: 15626057
Int J Drug Policy. 2009 Nov;20(6):509-13
pubmed: 19535239
Int J Environ Res Public Health. 2018 Oct 31;15(11):
pubmed: 30384494
Ethiop J Health Sci. 2011 Mar;21(1):37-45
pubmed: 22434984
World Health Organ Tech Rep Ser. 1985;729:1-31
pubmed: 3938107
Soc Sci Med. 2009 Oct;69(7):1040-8
pubmed: 19666207
Front Public Health. 2014 Jun 30;2:71
pubmed: 25072043
Health Qual Life Outcomes. 2014 Apr 04;12:44
pubmed: 24708622
Eur Addict Res. 2013;19(1):1-6
pubmed: 22948202
Int J Ment Health Syst. 2012 Jul 02;6(1):8
pubmed: 22747911
BMC Med. 2005 Feb 12;3:5
pubmed: 15707502
J Subst Abuse Treat. 2021 Oct;129:108373
pubmed: 34080544
Subst Abuse Rehabil. 2015 Feb 26;6:41-50
pubmed: 25750551
BMC Psychiatry. 2015 Apr 03;15:69
pubmed: 25879767
Ann Gen Psychiatry. 2020 Aug 09;19:44
pubmed: 32788922
BMC Res Notes. 2018 Sep 3;11(1):637
pubmed: 30176922
Health Qual Life Outcomes. 2020 Mar 30;18(1):82
pubmed: 32228624
Afr Health Sci. 2017 Sep;17(3):844-851
pubmed: 29085412
PLoS One. 2016 Jun 03;11(6):e0156258
pubmed: 27257990
PLoS One. 2020 Jul 30;15(7):e0236154
pubmed: 32730258
Soc Sci Med. 1983;17(12):783-93
pubmed: 6879237
Subst Abus. 2014;35(3):235-44
pubmed: 24965057
Subst Abuse Treat Prev Policy. 2020 Apr 3;15(1):27
pubmed: 32245382
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
PLoS Med. 2007 Dec;4(12):e341
pubmed: 18076280
East Mediterr Health J. 2021 Apr 27;27(4):353-360
pubmed: 33955531
PLoS One. 2011;6(6):e20602
pubmed: 21698275
Hum Psychopharmacol. 2018 Mar;33(2):e2653
pubmed: 29527722
Phytother Res. 2002 Aug;16(5):403-13
pubmed: 12203257
Scand J Public Health. 2008 Aug;36(6):589-97
pubmed: 18775815
BMC Public Health. 2014 Nov 21;14:1198
pubmed: 25416647
World Psychiatry. 2017 Oct;16(3):323
pubmed: 28941092
Neuropsychiatr Dis Treat. 2018 Oct 17;14:2755-2761
pubmed: 30425493
Soc Sci Med. 2007 Jul;65(2):309-18
pubmed: 17544193
Psychiatry J. 2020 Jan 06;2020:1462141
pubmed: 31970194
BMC Public Health. 2020 Jan 28;20(1):110
pubmed: 31992259
Int J Ment Health Syst. 2017 Jan 3;11:5
pubmed: 28053661
Acta Psychiatr Scand Suppl. 1999;397:84-91
pubmed: 10470360
Biomed Res Int. 2016;2016:2642506
pubmed: 27022605
Addiction. 2016 Sep;111(9):1666-76
pubmed: 27061394
Subst Abuse Rehabil. 2021 Aug 15;12:41-48
pubmed: 34429682
BMJ Open. 2022 Jul 25;12(7):e061865
pubmed: 35879018
Int J Drug Policy. 2016 Apr;30:27-34
pubmed: 26949190
Biomed Res Int. 2015;2015:604526
pubmed: 26380288
Biomed Res Int. 2013;2013:487232
pubmed: 23878809
Depress Res Treat. 2020 Jan 31;2020:5027918
pubmed: 32099677
BMC Res Notes. 2017 Jul 17;10(1):289
pubmed: 28716128
PLoS One. 2015 Mar 20;10(3):e0119464
pubmed: 25794278
PLoS One. 2012;7(3):e33946
pubmed: 22479484
Med J Aust. 2011 Dec 19;195(11-12):666-9
pubmed: 22171861
Addiction. 2008 Jul;103(7):1082-99
pubmed: 18422826
Cult Med Psychiatry. 2013 Mar;37(1):111-30
pubmed: 23192491
Eur Addict Res. 2011;17(6):285-91
pubmed: 21860244
PLoS One. 2020 Jan 16;15(1):e0227405
pubmed: 31945093
J Ethnopharmacol. 2010 Dec 1;132(3):615-9
pubmed: 19913607
Depress Res Treat. 2020 Sep 26;2020:7934892
pubmed: 33062330
Am J Addict. 2013 Mar-Apr;22(2):99-107
pubmed: 23414493
Curationis. 2007 Jun;30(2):74-81
pubmed: 17703825